Mitochondrial apoptosis and BH3 mimetics.
Mitochondrial apoptosis and BH3 mimetics.
复制标题
DOI：
10.12688/f1000research.9629.1
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Kaufmann SH
中科院分区：
文献类型：
--
作者：
Dai H;Meng XW;Kaufmann SH
bcl2选择性BH3模拟venetoclax最近被批准用于治疗复发的，染色体17p缺失的慢性淋巴细胞白血病（CLL），并且正在进行广泛的试验，单独或联合用于淋巴瘤，急性白血病和实体瘤。在此，我们总结了BCL2家族成员生物学的最新进展，揭示了BH3模拟物的作用，回顾了导致venetoclax获得监管批准的临床前和临床研究，并讨论了这类新型抗肿瘤药物的未来研究。
The BCL2-selective BH3 mimetic venetoclax was recently approved for the treatment of relapsed, chromosome 17p-deleted chronic lymphocytic leukemia (CLL) and is undergoing extensive testing, alone and in combination, in lymphomas, acute leukemias, and solid tumors. Here we summarize recent advances in understanding of the biology of BCL2 family members that shed light on the action of BH3 mimetics, review preclinical and clinical studies leading to the regulatory approval of venetoclax, and discuss future investigation of this new class of antineoplastic agent.